[BIIB] Biogen Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 287.53 Change: 4.46 (1.58%)
Ext. hours: 292.98 Change: 5.45 (1.9%)

chart BIIB

Refresh chart

Strongest Trends Summary For BIIB

BIIB is in the long-term up 166% above S&P in 20 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn?s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company?s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical tri

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS17.73 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.19% Sales Growth - Q/Q1.44% P/E14.2
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA20.83% ROE27.76% ROI24.82%
Current Ratio2.2 Quick Ratio1.86 Long Term Debt/Equity0.19 Debt Ratio0.2
Gross Margin88.36% Operating Margin45.28% Net Profit Margin33.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities77.22 M Cash From Investing Activities-1.76 B Cash From Operating Activities1.78 B Gross Profit2.31 B
Net Profit927.28 M Operating Profit1.23 B Total Assets16.76 B Total Current Assets5.62 B
Total Current Liabilities2.56 B Total Debt579.47 M Total Liabilities4.19 B Total Revenue2.59 B
Technical Data
High 52 week367.91 Low 52 week257.52 Last close358.11 Last change-0.11%
RSI84.19 Average true range11.63 Beta1.03 Volume1.07 M
Simple moving average 20 days10.98% Simple moving average 50 days17.89% Simple moving average 200 days16.97%
Performance Data
Performance Week3.01% Performance Month22.62% Performance Quart34.62% Performance Half3.97%
Performance Year27.01% Performance Year-to-date12.41% Volatility daily3.95% Volatility weekly8.83%
Volatility monthly18.1% Volatility yearly62.72% Relative Volume178.46% Average Volume1.85 M
New High New Low


2019-03-18 15:15:00 | Biogen Could Go Either Way - Mixed Indicators and Charts

2019-03-15 11:25:03 | PDL BioPharma PDLI Q4 Earnings Top Mark, Revenues Fall Y/Y

2019-03-13 09:18:01 | The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

2019-03-12 14:02:06 | Top Stock Reports for Visa, Honeywell & Biogen

2019-03-12 10:45:25 | Fujifilm snaps up Biogen manufacturing site, employees for $890M

2019-03-12 10:30:58 | See what the IHS Markit Score report has to say about Biogen Inc.

2019-03-12 10:07:02 | Celgene CELG Submits Application for MS Drug in Europe

2019-03-12 07:10:49 | Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

2019-03-12 03:00:00 | Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm

2019-03-11 13:41:42 | Mass. firms riding bull market to nearly $1 trillion in gains

2019-03-10 17:19:00 | Better Buy: Amgen vs. Biogen

2019-03-08 12:27:06 | 6 of the Most Expensive Stocks That Could Go On Sale

2019-03-08 10:40:00 | Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?

2019-03-06 10:26:03 | Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

2019-03-06 06:28:00 | Biotech Companies Slump Midday With FDA Chief Set to Leave

2019-03-05 16:53:09 | Biogen to Acquire Gene-Therapy Company Nightstar for $800M

2019-03-05 16:37:38 | How Much Does Biogen Gain From Its $800 Million Gene Therapy Buyout?

2019-03-05 13:01:09 | Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar

2019-03-05 09:43:02 | Company News For Mar 5, 2019

2019-03-04 17:01:53 | Stock Market Today: Biogen Buys Gene Therapy Company Nightstar Therapeutics

2019-03-04 16:24:28 | Biogen Shores Up Gene Therapy Assets With $800 Million Takeover

2019-03-04 15:46:00 | Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs

2019-03-04 12:57:54 | NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy

2019-03-04 12:43:00 | Nightstar Stock Is Latest Winner From Gene-Therapy Gold Rush

2019-03-04 12:37:13 | Biogen Buys Nightstar Therapeutics in $800 Million Deal

2019-03-04 12:28:04 | Can You Imagine How Biogen’s Shareholders Feel About The 24% Share Price Increase?

2019-03-04 11:35:24 | Why NightStar Therapeutics Is Soaring Today

2019-03-04 10:56:18 | Biogen Makes Gene Therapy Splash as Street Wonders What's Next

2019-03-04 10:51:15 | AT&T makes big media changes, Children's Place disappoints, Kellogg's bets on vegan foods

2019-03-04 10:05:03 | AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab

2019-03-04 09:42:00 | Why Nightstar Therapeutics Stock Is Soaring Today

2019-03-04 09:33:00 | Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

2019-03-04 09:11:21 | Biogen Bets On Gene Therapy, Agrees To Acquire Nightstar For $800M

2019-03-04 08:39:00 | Nightstar Therapeutics' stock rockets on Biogen buyout deal valued at $877 million

2019-03-04 07:05:46 | [$$] Biogen Buys Gene Therapy for Rare Eye Disease

2019-03-04 03:30:00 | Stocks - Tesla, AT&T, Amazon, Facebook Rise in Premarket

2019-03-04 03:07:06 | Biogen to buy Nightstar Therapeutics in $800 mln cash deal

2019-03-04 02:00:00 | Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology

2019-03-01 20:18:44 | Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA

2019-02-28 14:30:08 | 8 High Margin Stocks to Lead in a Sharply Slowing Economy

2019-02-28 07:30:00 | Biogen Further Expands Presence in China with Approval of SPINRAZA® nusinersen, the First and Only Treatment for Spinal Muscular Atrophy

2019-02-27 19:52:33 | Ionis Pharmaceuticals IONS Q4 2018 Earnings Conference Call Transcript

2019-02-27 14:35:00 | Here's Why Ionis Pharmaceuticals Jumped Higher Today

2019-02-26 08:32:01 | Alkermes' ALKS and Biogen's NDA for BIIB098 Accepted by FDA

2019-02-25 10:27:03 | Novartis In-Licenses Rights to Heart Candidate From Ionis

2019-02-25 08:10:00 | Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-25 07:30:00 | Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

2019-02-24 10:46:09 | Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers

2019-02-22 17:49:43 | Novartis gene therapy would be cost effective up to $900,000 -U.S. group

2019-02-22 08:00:57 | The Top 5 Biotech Stocks Are Facing Growth Challenges — Are Any Immune?